Gilead Sciences, Inc.
GILDHealthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024.
- Revenue
- +6.83%
- EPS
- −20.2%
- Free cash flow
- +21.1%
- Total debt
- +5.17%
Quarter to September 2026, against a year earlier
Follow GILD
Alert me
Gilead Sciences, Inc. 10-K filed Feb 24, 2026
What changed
Item 1, Business, against the 10-K filed Feb 28, 2025: 4 added · 9 removed · 34 modified; 3 with only figures updated; 6 moved without change
-
Modified
Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis,
coronavirus disease 2019 (“COVID-19”), cancerandinflammationcancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California.